Prognostic value of lymph node density on cancer staging system for gastric cancer without distal metastasis: a population-based analysis of SEER database

Yuhua Liu¹²†, Hao Cui¹³†, Xinxin Xu¹³† and Wenquan Liang¹³*

Abstract
Background: Accurate tumor staging is the cornerstone of tumor treatment. Current tumor staging system for gastric cancer (GC) is based on regional positive lymph nodes while ignoring the total number of examined lymph nodes. We aim to assess the prognostic value of lymph node density (LND), the ratio of positive nodes to the total number examined nodes, in GC without distal metastasis.

Methods: Clinical information of patients with histologically confirmed GC and without distal metastasis was identified from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. The X-Tile software was used to identify the ideal prognosis-related cutoff point for LND. The prognostic value of LND on cancer-specific survival (CSS) and overall survival (OS) was assessed in Cox regression models. Subgroup analysis stratified by LND was performed on current lymph node staging system to further explore the interaction between LND and current lymph node staging system.

Results: A total of 4281 participants were identified from the SEER database for the final analysis. The optimal prognosis-related cutoff values of LND were calculated as 0.1 and 0.4, and LND was divided into three levels: LND1 (< 0.1), LND2 (≥ 0.1, < 0.4), and LND3 (≥ 0.4). LND3 was associated with worse CSS and OS in GC patients. Compared to patients with LND1, those with LND2 and LND3 had 2.43 (HR = 2.43, 95% CI 2.09–2.84, P < 0.001) and 4.69 (HR = 4.69, 95% CI 4.02–5.48, P < 0.001) folds increase in mortality in CSS, respectively. Similar results were found in the evaluation of OS in GC patients. Subgroup analysis stratified by LND also found that patients in the same current lymph node stage still had different prognosis due to the different LND levels after adjustment for other prognosis-related covariates (all P values < 0.001).

Conclusion: LND is an independent prognostic factor for GC without distal metastasis. In the current lymph node staging system, LND has potential value in further accurately classifying GC patients without distal metastasis.

Keywords: Lymph node density, Gastric cancer, SEER, Tumor staging, Overall survival, Cancer-specific survival

Background
Gastric cancer (GC) is the fourth most commonly diagnosed cancer on the upper digestive system and remains the second most common cause of cancer-related deaths worldwide [1]. Cancer staging is the cornerstone of successful tumor therapy after surgery. Today, the American
Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) classification is the most widely used staging system for GC [2–4]. Lymph node staging system, also defined as N category, is an essential factor for predicting prognosis and selecting the appropriate treatment [5]. In the AJCC staging system, only the number of positive regional nodes is taken into account and the number of the total examined regional nodes does not get enough attention [6, 7]. However, GC patients with same number of regional positive nodes accompanying with more total regional nodes examined tend to have a higher level of radical gastrectomy and lower risk with the residual tumor [8, 9]. New attempt and exploring an evaluating criterion of the lymph node staging system is needed.

Several studies have demonstrated that GC patients with more examined regional nodes were more likely to have better survival because they tended to have a higher level of radical gastrectomy [10–12]. With the development of surgical techniques, obtaining and examining an increasing number of total regional nodes is no longer difficult for an experienced surgeon. Lymph node density (LND), also called lymph node ratio (LNR), is calculated by the ratio of the number of positive nodes to the total examined nodes [13, 14]. This parameter has been proven as a potential prognostic factor in several cancers, including GC [15, 16]. From the 7th edition (the year 2010) of the AJCC staging system, resection of at least 16 regional lymph nodes was introduced into the guideline of GC surgery [17]. The number of lymph node dissection before 2010 was small, usually less than 15, and previous studies of LND in GC were limited because they enrolled the patients both before and after 2010 [18]. The prognostic value of LND needs to be reassessed by only using data after 2010, which is same as the current lymph node dissection standard.

In the present study, we determined the impact of LND on cancer-specific survival (CSS) and overall survival (OS) in GC patients based on data after 2010 in the Surveillance, Epidemiology, and End Results (SEER) database. We hypothesize that LND is an independent prognostic factor in GC. The interaction between LND and current lymph node staging system was detected to provide evidence for the development of a novel accurate lymph node staging strategy.

Methods

Patients and data

This study had a retrospective design and included data from patients with histologically confirmed GC from the SEER database. Data were recorded according to the third edition of the International Classification of Diseases for Oncology. Enrollment occurred between 2010 and 2015, during which period the 7th AJCC staging strategies were applied and the follow-up and treatment information was complete. Patients were included if they were older than 18 years and had undergone gastrectomy. Patients with neoadjuvant radiotherapy were removed from the analysis, and only those with a histological type of adenocarcinoma were enrolled. Patients with incomplete data regarding tumor location or staging information were also excluded from the analysis. The primary variable in this study was lymph node data and patients lacking information regarding the exact number of nodes examined or positive nodes were not included in the analysis. In the 7th edition (2010) of the AJCC staging system for gastric cancer, the cutoff levels of N category were as follows: N0 = 0 node; N1 = 1–2 nodes; N2 = 3–6 nodes; N3 = more than 6 nodes. The patient screening process is shown in Fig. 1. Finally, a total number of 4281 patients with GC were included for analysis in the present study.

The following available information on pathological and clinical appearance was collected from data-mining: age at diagnosis, sex, year of diagnosis, race, marital status at diagnosis, insurance status, primary site, 7th AJCC stage group information, grade, chemotherapy, lymph node data, cause-specific death classification, vital status recode, and survival months. Overall survival (OS) was determined with the vital status recode and survival months, while cancer-specific survival (CSS) was calculated with the cause-specific death classification and survival months. Informed consent was not obtained for the present study because of the open-source nature of the SEER database. This study was conducted in accordance with the Declaration of Helsinki.

Statistical analyses

LND was calculated by the ratio between the number of positive nodes and the number of examined nodes. Means were calculated for continuous variables and proportions for categorical variables. To identify the ideal cutoff point of LND in predicting survival, the X-Tile software (3.6.1 version, Yale University) was used [19]. The chi-square test (categorical variables), one-way analysis of variance (normal distribution), or the Mann-Whitney U test (skewed distribution) was used to test for differences among different LND groups. The relationship between specific variables and survival were analyzed by the Kaplan-Meier log-rank test and Cox proportional hazards regression. Univariate analyses of individual pathological and clinical features and CSS or OS were performed. To identify any independent association between LND and survival, we constructed three models: non-adjusted model, where no covariates were adjusted; adjusted I model, where only sociodemographic data of age, sex, and race were adjusted and adjusted II model, where covariates in the adjusted I model and other elected covariates were adjusted. If the matched odds ratio
changed at least 10% as the result of adding covariates, the variables were considered to be added in the adjusted II model, as described in a previous study [20]. To estimate the robustness of LND in predicting survival, sensitivity analyses were stratified according to different AJCC N stages. Tests for effect modification for those of subgroup indicators were followed by the likelihood ratio test. All the analyses were performed with the statistical software package R (http://www.R-project.org, The R Foundation) and EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA). $P$ values less than 0.05 (two-sided) were considered statistically significant.

**Results**

**Demographic characteristics and relationship between LND and clinical features**

After screening by inclusion and exclusion criteria, a total of 4281 participants diagnosed with GC were selected from the SEER database for the final data analysis. Table 1 provides an overview of patient characteristics and clinicopathologic features. The average age at diagnosis was 69.73 years for the whole population enrolled, and almost two-thirds of the participants (63.78%) were male. The number of enrolled patients was evenly distributed throughout the enrollment period from 2010 to 2015. Other baseline demographic data and information on pathologic staging and grading are shown in Table 1. The X-Tile software was used to identify the ideal cutoff point for LND in predicting survival. As shown in Supp. Figure S1 and S2, cutoff points of 0.1 and 0.4 yielded the maximum chi-square of log-rank tests for CSS and OS, and LND was divided into three levels: LND1, LND2, and LND3. The survival difference was significant in the three groups both for CSS and OS when divided by the best cutoff points. The relationship between different groups of LND and clinical features is shown in Table 1. Insured patients tended to have a lower level of LND than that uninsured or unknown categories, indicating that the insured population may have easier access to physical examinations and thus receive an earlier diagnosis. Tumors located on the upper stomach tended to have a lower level of LND and tumors with overlapping lesions tended to have a higher level of LND. A high rate of

---

Fig. 1 Flow chart illustrating the screening process in this study

| Case of diagnosed GC from 2010 to 2015, age 18+ years, with resection of primary site, without distant metastasis (n=27,451) | Neoadjuvant radiotherapy, or unknown (n=4,247) |
| No neoadjuvant therapy (n=23,204) | Not adenocarcinomas (n=5,216) |
| Gastric adenocarcinomas (n=17,988) | Primary site unknown (n=1,319) |
| Well-defined tumor location (n=16,689) | T0, Tis or Tx (n=5,812) N0 (n=1,096) |
| Complete staging data (n=9,761) | Without exact number of nodes examined (n=2,440) |
| Complete lymph node data (n=4,281) | Without exact number of regional nodes positive (n=3,040) |
| Variables                              | Total    | LND1 (< 0.1) | LND2 (≥ 0.1, < 0.4) | LND3 (≥ 0.4) | P value |
|----------------------------------------|----------|--------------|---------------------|--------------|---------|
| Patients, n                            | 4821     | 3170         | 871                 | 780          |         |
| Regional nodes examined                | 17.96 ± 12.67 | 17.63 ± 12.64 | 20.02 ± 12.65     | 17.01 ± 12.58 | < 0.001 |
| Regional nodes positive                | 2.69 ± 5.40   | 0.20 ± 0.57  | 4.27 ± 3.14        | 11.09 ± 8.32  | < 0.001 |
| Age at diagnosis (years)               | 69.73 ± 12.30 | 69.47 ± 11.98 | 70.18 ± 12.65     | 70.24 ± 13.12 | 0.143   |
| Sex                                    |          |              |                     |              | 0.291   |
| Male                                   | 3075 (63.78%) | 2033 (64.13%) | 536 (61.54%)       | 506 (64.87%)  |         |
| Female                                 | 1746 (36.22%) | 1137 (35.87%) | 335 (38.46%)       | 274 (35.13%)  |         |
| Year of diagnosis                      |          |              |                     |              | 0.225   |
| 2010                                   | 842 (17.47%) | 536 (16.91%)  | 170 (19.52%)       | 136 (17.44%)  |         |
| 2011                                   | 816 (16.93%) | 523 (16.50%)  | 143 (16.42%)       | 150 (19.23%)  |         |
| 2012                                   | 826 (17.13%) | 538 (17.60%)  | 138 (15.84%)       | 130 (16.67%)  |         |
| 2013                                   | 780 (16.18%) | 500 (15.77%)  | 147 (16.88%)       | 133 (17.05%)  |         |
| 2014                                   | 800 (16.59%) | 527 (16.62%)  | 147 (16.88%)       | 126 (16.15%)  |         |
| 2015                                   | 757 (15.70%) | 526 (16.59%)  | 126 (14.47%)       | 105 (13.46%)  |         |
| Race                                   |          |              |                     |              | 0.229   |
| White                                  | 3121 (64.74%) | 2024 (65.85%) | 573 (65.79%)       | 524 (67.18%)  |         |
| Asian or Pacific Islander              | 1019 (21.14%) | 692 (21.83%)  | 180 (20.67%)       | 147 (18.85%)  |         |
| Black                                  | 629 (13.05%) | 413 (13.03%)  | 113 (12.97%)       | 103 (13.21%)  |         |
| Other                                  | 52 (1.08%)  | 41 (1.29%)    | 5 (0.57%)          | 6 (0.77%)    |         |
| Marital status at diagnosis            |          |              |                     |              | 0.068   |
| Married                                | 2840 (58.91%) | 1900 (59.94%) | 499 (57.29%)       | 441 (56.54%)  |         |
| Widowed                                | 738 (15.31%) | 474 (14.95%)  | 140 (16.07%)       | 124 (15.90%)  |         |
| Single                                 | 624 (12.94%) | 377 (11.89%)  | 126 (14.47%)       | 121 (15.51%)  |         |
| Other                                  | 619 (12.84%) | 419 (13.22%)  | 106 (12.17%)       | 94 (12.05%)   |         |
| Insurance                              |          |              |                     |              | 0.012   |
| Insured                                | 2950 (61.19%) | 1981 (62.49%) | 536 (60.39%)       | 443 (56.79%)  |         |
| Uninsured or unknown                   | 1871 (38.81%) | 1189 (37.51%) | 345 (39.61%)       | 337 (43.21%)  |         |
| Primary site                           |          |              |                     |              | < 0.001 |
| Upper                                  | 1300 (26.97%) | 931 (29.37%)  | 230 (26.41%)       | 139 (17.82%)  |         |
| Middle                                 | 1433 (29.72%) | 955 (30.13%)  | 254 (29.16%)       | 224 (28.72%)  |         |
| Lower                                  | 1702 (35.30%) | 1092 (34.45%) | 298 (34.21%)       | 312 (40.00%)  |         |
| Overlapping lesion                     | 386 (8.01%)  | 192 (6.06%)   | 89 (10.22%)        | 105 (13.46%)  |         |
| AJCC stage group, 7th (2010-2015)      |          |              |                     |              | < 0.001 |
| Stage I                                | 1910 (39.62%) | 1877 (59.21%) | 27 (3.10%)         | 6 (0.77%)    |         |
| Stage II                               | 1287 (26.70%) | 1010 (31.86%) | 207 (23.77%)       | 70 (8.97%)   |         |
| Stage III                              | 1624 (33.69%) | 283 (8.93%)   | 637 (73.13%)       | 704 (90.26%)  |         |
| Variables          | Total     | LND1 (< 0.1) | LND2(> = 0.1, < 0.4) | LND3 (> = 0.4) | P value |
|-------------------|-----------|--------------|----------------------|----------------|---------|
| **AJCC T, 7th (2010-2015)** |           |              |                      |                |         |
| T1                | 1644 (34.10%) | 1539 (48.55%) | 80 (9.18%)           | 25 (3.21%)     | <0.001  |
| T2                | 708 (14.69%)  | 554 (17.48%)  | 98 (11.25%)          | 56 (7.18%)     |         |
| T3                | 1577 (32.71%) | 829 (26.19%)  | 416 (47.76%)         | 332 (42.56%)   |         |
| T4                | 892 (18.50%)  | 248 (7.82%)   | 277 (31.80%)         | 367 (47.05%)   |         |
| **AJCC N, 7th (2010-2015)** |           |              |                      |                | <0.001  |
| N0                | 2607 (54.08%) | 2607 (82.24%) | 0 (0.00%)            | 0 (0.00%)      |         |
| N1                | 913 (18.94%)  | 494 (15.58%)  | 317 (36.39%)         | 102 (13.08%)   |         |
| N2                | 642 (13.32%)  | 67 (2.11%)    | 405 (46.50%)         | 170 (21.79%)   |         |
| N3                | 659 (13.67%)  | 2 (0.06%)     | 149 (17.11%)         | 508 (65.13%)   |         |
| **Grade**         |           |              |                      |                | <0.001  |
| Well differentiated| 515 (10.68%) | 474 (14.99%)  | 27 (3.10%)           | 14 (1.79%)     |         |
| Moderately differentiated | 1656 (34.35%) | 1243 (39.21%) | 258 (29.62%)       | 155 (19.87%)   |         |
| Poorly differentiated | 2570 (53.31%) | 1404 (44.29%) | 577 (66.25%)       | 589 (75.51%)   |         |
| Undifferentiated, anaplastic | 80 (1.66%) | 49 (1.55%) | 9 (1.03%) | 22 (2.82%) |         |
| **Chemotherapy**  |           |              |                      |                | <0.001  |
| No/unknown        | 3362 (69.74%) | 2434 (76.78%) | 456 (52.35%)        | 472 (60.51%)   |         |
| Yes               | 1459 (30.26%) | 736 (23.22%)  | 415 (47.65%)        | 308 (39.49%)   |         |

**Abbreviations:** LND lymph node density, OR odds ratio, CI confidence interval
LND in advanced AJCC staging and grading is clearly shown in Table 1. This result is somewhat counterintuitive and requires further investigation since patients in the middle level of LND were more likely to receive chemotherapy.

**Association between clinical variables and CSS and OS**

Table 2 shows the prognostic factors affecting CSS and OS in GC patients based on univariate analysis. Older age was significantly associated with reduced CSS (HR = 1.01, 95% CI 1.01–1.01, P < 0.001) and OS (HR = 1.03, 95% CI 1.02–1.03, P < 0.001). Null associations of sex were observed with CSS and OS. The mortality of GC patients was reduced with an increase in the year of diagnosis, although this result was just short of being statistically significant. The effect of race was also assessed, with Asian or Pacific islander populations showing a lower risk of mortality than white patients in CSS (HR = 0.79, 95% CI 0.68–0.92, P = 0.002) and OS (HR = 0.71, 95% CI 0.63–0.80, P < 0.001). Marital status at diagnosis was associated with GC survival and being widowed and single was associated with a dismal prognosis in CSS and OS analysis. Uninsured patients or those with unknown insurance status were at high risk of death in CSS (HR = 1.21, 95% CI 1.08–1.35, P = 0.001) and OS (HR = 1.13, 95% CI 1.03–1.23, P = 0.007). Compared to upper GC, primary tumors located at overlapping lesions significantly increased the risk of mortality both in CSS analysis (HR = 1.48, 95% CI 1.21–1.82, P = 0.001) and OS (HR = 1.36, 95% CI 1.16–1.60, P = 0.001). There was a significant positive correlation between advanced AJCC staging and survival both in CSS and OS (all P values < 0.001), which was in accordance with our clinical experience. In addition, patients with poorly or undifferentiated GC had an approximately doubled mortality risk compared to those with well-differentiated tumors. Patients receiving chemotherapy had a 1.33-fold increase in mortality risk in CSS analysis than those without chemotherapy or unknown chemotherapy status (HR = 1.33, 95% CI 1.19–1.50, P < 0.001), but the association was not significant in OS analysis. The primary variable in this study was LND and its survival predicting effects were fully investigated. Patients in LND2 or LND3 had 3.98 (95% CI 3.45–4.60, P < 0.001), 8.57 (95% CI 7.48–9.82, P < 0.001) folds increase in mortality risk in CSS, respectively, than those in LND1. Differences in mortality rate of OS were also shown for patients in the LND2 or LND3 which had 2.88 (95% CI 2.59–3.20, P < 0.001) and 5.54 (95% CI 4.99–6.15, P < 0.001) fold increase in mortality risk compared to those with the lower level. Kaplan–Meier survival curves for those patients according to LND status are presented in Fig. 2. Significant differences were observed among LND subgroups in predicting CSS (Fig. 2A, P < 0.001) and OS (Fig. 2B, P < 0.001).

**Independent prognostic effect of LND and stratified effect analysis in current lymph node staging systems**

To further elucidate the prognostic impact of LND on GC patients who underwent gastrectomy, Cox multivariate analysis was performed (Table 3). We constructed three models to analyze the independent effects of LND on survival including a crude (non-adjusted) model, minimally adjusted (adjusted I) model and fully adjusted (adjusted II) model. As previously shown in the results of multivariate analysis, CSS and OS of GC patients decreased with an increase in LND in different models. In the fully adjusted model, compared to the lower LND group, patients with a middle and higher level of LND had 2.43 (HR = 2.43, 95% CI 2.09–2.84, P < 0.001) and 4.69 (HR = 4.69, 95% CI 4.02–5.48, P < 0.001) fold increase in mortality in CSS, respectively. Similar results were found in the evaluation of OS which showed that patients with a middle and higher level of LND had 2.04 (HR = 2.04, 95% CI 1.81–2.29, P < 0.001) and 3.61 (HR = 3.61, 95% CI 3.20–4.07, P < 0.001) fold increase in mortality, respectively. Taken together, these data suggest that LND had independent prognostic effects in patients with GC.

To further elucidate whether LND had independent prognostic effects in the current nodal category strategies, subgroup analysis was performed. Each positive N category (N1-3) was stratified into different LND subgroups. In the N1 and N2 stages, patients with GC were divided into three groups according to the cutoff points of LND. As shown in Table 3, CSS and OS of GC patients significantly decreased with the increase in LND grade in different models (all P values < 0.05). For patients in the N3 stage, there were only two patients in LND1 group (Table 1) and thus for patients in the N3 category the cutoff point was 0.4. Results repeatedly showed that a high level of LND was associated with worse survival in CSS and OS in different models (all P values < 0.05). In addition, survival curves were plotted using the Kaplan-Meier method to determine the independent prognostic effect of LND in subgroups of N categories. As presented in Fig. 3, patients in each positive N category were found to contain subgroups divided by LND, with significantly heterogeneous CSS and OS (all P values < 0.001).

**Discussion**

Accurate staging is the cornerstone of optimal cancer care and therapy. The current staging system of N categories, the AJCC TNM system, for GC patients is based on the number of lymph nodes with metastases and the number of examined lymph nodes is not taken into account. The prognostic role of LND, calculated by the ratio of the number of positive nodes to the number of
Table 2  Association between clinical variables and gastric cancer-specific survival or overall survival

| Variables                                      | CSS, HR (95%CI) | P value | OS, HR (95%CI) | P value |
|------------------------------------------------|-----------------|---------|----------------|---------|
| Age at diagnosis (years)                       | 1.01 (1.01, 1.01) | < 0.001 | 1.03 (1.02, 1.03) | < 0.001 |
| Sex                                            |                 |         |                |         |
| Male                                           | Ref.            |         | Ref.           |         |
| Female                                         | 0.96 (0.86, 1.08) | 0.536   | 0.92 (0.84, 1.00) | 0.061   |
| Year of diagnosis                              |                 |         |                |         |
| 2010                                           | Ref.            |         | Ref.           |         |
| 2011                                           | 1.13 (0.95, 1.35) | 0.151   | 0.99 (0.87, 1.13) | 0.866   |
| 2012                                           | 0.90 (0.75, 1.08) | 0.272   | 0.90 (0.78, 1.03) | 0.121   |
| 2013                                           | 0.98 (0.81, 1.18) | 0.841   | 0.95 (0.83, 1.10) | 0.516   |
| 2014                                           | 0.91 (0.74, 1.11) | 0.336   | 0.89 (0.77, 1.04) | 0.141   |
| 2015                                           | 0.91 (0.72, 1.13) | 0.384   | 0.79 (0.66, 0.94) | 0.009   |
| Race                                           |                 |         |                |         |
| White                                          | Ref.            |         | Ref.           |         |
| Asian or Pacific islander                      | 0.79 (0.68, 0.92) | 0.002   | 0.71 (0.63, 0.80) | < 0.001 |
| Black                                          | 1.03 (0.87, 1.21) | 0.740   | 1.02 (0.90, 1.16) | 0.079   |
| Other                                          | 0.76 (0.42, 1.38) | 0.372   | 0.65 (0.40, 1.05) | 0.027   |
| Marital status at diagnosis                    |                 |         |                |         |
| Married                                        | Ref.            |         | Ref.           |         |
| Widowed                                        | 1.40 (1.20, 1.63) | < 0.001 | 1.52 (1.36, 1.71) | < 0.001 |
| Single                                         | 1.32 (1.12, 1.56) | 0.001   | 1.26 (1.11, 1.43) | 0.001   |
| Other                                          | 0.99 (0.83, 1.18) | 0.372   | 1.08 (0.95, 1.24) | 0.242   |
| Insurance                                      |                 |         |                |         |
| Insured                                        | Ref.            |         | Ref.           |         |
| Uninsured or unknown                           | 1.21 (1.08, 1.35) | 0.001   | 1.13 (1.03, 1.23) | 0.007   |
| Primary site                                   |                 |         |                |         |
| Upper                                          | Ref.            |         | Ref.           |         |
| Middle                                         | 0.96 (0.82, 1.11) | 0.553   | 0.98 (0.87, 1.10) | 0.699   |
| Lower                                          | 1.03 (0.90, 1.19) | 0.646   | 1.10 (0.98, 1.22) | 0.093   |
| Overlapping lesion                             | 1.48 (1.21, 1.82) | 0.001   | 1.36 (1.16, 1.60) | 0.001   |
| AJCC stage group, 7th (2010-2015)              |                 |         |                |         |
| Stage I                                        | Ref.            |         | Ref.           |         |
| Stage II                                       | 3.40 (2.79, 4.13) | < 0.001 | 2.12 (1.87, 2.40) | < 0.001 |
| Stage III                                      | 9.75 (8.18, 11.62) | < 0.001 | 4.80 (4.30, 5.35) | < 0.001 |
| AJCC T, 7th (2010-2015)                        |                 |         |                |         |
| T1                                             | Ref.            |         | Ref.           |         |
| T2                                             | 1.99 (1.56, 2.55) | < 0.001 | 1.44 (1.23, 1.69) | < 0.001 |
| T3                                             | 4.76 (3.96, 5.73) | < 0.001 | 2.81 (2.50, 3.16) | < 0.001 |
| T4                                             | 10.10 (8.36, 12.20) | < 0.001 | 5.16 (4.55, 5.85) | < 0.001 |
| AJCC N, 7th (2010-2015)                        |                 |         |                |         |
| N0                                             | Ref.            |         | Ref.           |         |
| N1                                             | 3.35 (2.85, 3.94) | < 0.001 | 2.27 (2.02, 2.55) | < 0.001 |
| N2                                             | 5.02 (4.24, 5.93) | < 0.001 | 3.13 (2.77, 3.55) | < 0.001 |
| N3                                             | 9.14 (7.84, 10.67) | < 0.001 | 5.32 (4.75, 5.96) | < 0.001 |
| Grade                                          |                 |         |                |         |
| Well differentiated                            | Ref.            |         | Ref.           |         |
| Moderately differentiated                     | 1.91 (1.42, 2.56) | < 0.001 | 1.57 (1.30, 1.89) | < 0.001 |
| Poorly differentiated                          | 3.96 (2.99, 5.23) | < 0.001 | 2.46 (2.06, 2.95) | < 0.001 |
| Undifferentiated; anaplastic                   | 3.82 (2.35, 6.20) | < 0.001 | 2.64 (1.86, 3.74) | < 0.001 |
examined nodes, in GC staging was analyzed in the present study. Optimal cutoff values of LND were calculated as 0.1 and 0.4, and LND was divided into three levels: LND1 (< 0.1), LND2 (≥ 0.1, < 0.4), and LND3 (≥ 0.4). Significant differences in survival were observed among LND subgroups and in predicting CSS and OS by univariate analysis. We constructed three models to analyze the independent effects of LND on survival and results showed that LND had independent prognostic effects in patients with GC. To evaluate the performance of LND in the staging system, each N category was stratified by different levels of LND. Each N category was found to contain subgroups of GC patients with significantly heterogeneous CSS and OS.

Currently, the AJCC TNM system is the most commonly used staging system for GC. From the 7th edition AJCC staging manual, the N category was recommended to include resection of at least 16 regional lymph nodes [17, 21]. A considerable amount of literature has been published on the topic of LND or LNR from 2010, when the 7th edition AJCC staging manual firstly came into efforts [22, 23]. Many studies have demonstrated that regional positive nodes did not or insufficiently reflect the survival of patients with GC [14, 24, 25]. For patients who were detected with the same number of regional positive nodes, those with more regional nodes examined were more likely to have better survival because those patients tended to be with a higher level of radical gastrectomy and have lower risk with the residual tumor. Validation analysis from Taiwan University Hospital Cancer Registry also found the advantages of a staging system using a lymph node ratio using a patient cohort from Eastern medical centers [26]. One study from China showed that the lymph node ratio staging system is a reliable classification for GC patients after neoadjuvant radiotherapy [27].

In the present study, we demonstrated that LND was an independent predictor of patients’ survival and to have stratified effects in different N subgroups. Although these findings have already been reported in previous studies [18, 22, 25, 26, 28], and some of these also used data from the SEER database [18, 25], our study has distinct characteristics that make it differ from previous studies. The time of enrolment in the present study was from 2010 to

### Table 2 (continued)

| Variables | CSS, HR (95%CI) | P value | OS, HR (95%CI) | P value |
|-----------|----------------|---------|----------------|---------|
| Chemotherapy | | | | |
| No/unknown | Ref. | | Ref. | |
| Yes | 1.33 (1.19, 1.50) | < 0.001 | 0.99 (0.90, 1.08) | 0.776 |
| LND | | | | |
| LND1 (< 0.1) | Ref. | | Ref. | |
| LND2 (≥ 0.1, < 0.4) | 3.98 (3.45, 4.60) | < 0.001 | 2.88 (2.59, 3.20) | < 0.001 |
| LND3 (≥ 0.4) | 8.57 (7.48, 9.82) | < 0.001 | 5.54 (4.99, 6.15) | < 0.001 |

**Abbreviations:** LND lymph node density, CSS cancer-specific survival, OS overall survival, HR hazard ratio, CI confidence interval

![Fig. 2](image-url)  
**Fig. 2** Kaplan–Meier survival curves of cancer-specific survival (A) and overall survival (B) for gastric cancer patients according to LND status.
Table 3  Multiple regression analysis to assess the independent effect in CSS and OS and stratified effect analysis in different N stages

| LND   | Non-adjusted                      | Adjust I                                        | Adjust II                                       |
|-------|-----------------------------------|------------------------------------------------|------------------------------------------------|
|       | CSS, HR (95%CI) P value           | OS, HR (95%CI) P value                         | CSS, HR (95%CI) P value                       |
|       | Total (n = 4821)                  |                                                 |                                                 |
|       | LND1(< 0.1) Ref.                  | Ref                                             | Ref                                             |
|       | LND2(> = 0.1, < 0.4) 3.98 (3.45, 4.60) < 0.001 | 2.88 (2.59, 3.20) < 0.001 | 3.97 (3.44, 4.58) < 0.001 | 2.84 (2.56, 3.16) < 0.001 | 2.43 (2.09, 2.84) < 0.001 | 2.04 (1.81, 2.29) < 0.001 |
|       | LND3(> = 0.4) 8.57 (7.48, 9.82) < 0.001 | 5.54 (4.99, 6.15) < 0.001 | 8.62 (7.52, 9.87) < 0.001 | 5.58 (5.03, 6.19) < 0.001 | 4.69 (4.02, 5.48) < 0.001 | 3.61 (3.20, 4.07) < 0.001 |
| Subgroup analysis |                           |                                                 |                                                 |
| N1 (n = 913) |                                           |                                                 |                                                 |
|       | LND1(< 0.1) Ref.                  | Ref                                             | Ref                                             |
|       | LND2(> = 0.1, < 0.4) 2.23 (1.72, 2.88) < 0.001 | 2.21 (1.81, 2.69) < 0.001 | 2.17 (1.67, 2.81) < 0.001 | 2.04 (1.67, 2.50) < 0.001 | 1.97 (1.51, 2.57) < 0.001 | 1.86 (1.52, 2.29) < 0.001 |
|       | LND3(> = 0.4) 3.59 (2.58, 4.98) < 0.001 | 3.18 (2.44, 4.14) < 0.001 | 3.39 (2.43, 4.72) < 0.001 | 2.88 (2.21, 3.76) < 0.001 | 3.12 (2.21, 4.39) < 0.001 | 2.65 (2.01, 3.49) < 0.001 |
| N2 (n = 642) |                                           |                                                 |                                                 |
|       | LND1(< 0.1) Ref.                  | Ref                                             | Ref                                             |
|       | LND2(> = 0.1, < 0.4) 2.17 (1.25, 3.75)0.005 | 2.46 (1.54, 3.92)0.002 | 2.15 (1.24, 3.73)0.006 | 2.44 (1.53, 3.90)0.002 | 2.07 (1.19, 3.60)0.10 | 2.34 (1.46, 3.76)0.001 |
|       | LND3(> = 0.4) 4.77 (2.72, 8.38) < 0.001 | 5.07 (3.13, 8.21) < 0.001 | 4.72 (2.68, 8.30) < 0.001 | 4.88 (3.01, 7.92) < 0.001 | 4.71 (2.63, 8.46) < 0.001 | 4.87 (2.96, 8.01) < 0.001 |
| N3 (n = 659) |                                           |                                                 |                                                 |
|       | LND < 0.4 Ref.                    | Ref                                             | Ref                                             |
|       | LND > = 0.4 2.51 (1.87, 3.38) < 0.001 | 1.86 (1.50, 2.31) < 0.001 | 2.07 (1.60, 2.70) < 0.001 | 1.92 (1.54, 2.39) < 0.001 | 1.94 (1.49, 2.53) < 0.001 | 1.80 (1.44, 2.25) < 0.001 |

Non-adjusted model did not adjust covariant
Adjusted I model minimally adjusted for sex, age, and race
Adjusted II model fully adjusted for sex, age, race, marital status at diagnosis, insurance, AJCC Stage Group 7th (2010-2015), AJCC T 7th (2010-2015), and grade
Abbreviations: LND lymph node density, CSS cancer-specific survival, OS overall survival, HR hazard ratio, CI confidence interval
2015, during which period the 7th AJCC staging strategies were applied and the follow-up and treatment information was complete. Most previous studies enrolled GC patients across a long-time span, and patients before 2010 were also included for analysis. Another consideration is that, before the application of the 7th AJCC staging system, the number of examined lymph nodes may have been lower. A recent study by Yang et al. included GC patients from the SEER database between 1988 and 2015 and 61.31% of patients had less than 15 examined lymph nodes.

Fig. 3 Stratified effect analysis of LND in positive N stages. Kaplan–Meier survival curves of cancer-specific survival in N1 (A), N2 (C), and N3 (E) subgroups. Kaplan–Meier survival curves of overall survival in N1 (B), N2 (D), and N3 (F) subgroups.
nodes [18, 29]. LND or lymph node ratio is determined by the number of positive regional nodes and the number of examined regional nodes. With the development of surgical techniques, an increasing number of regional nodes can be resected and examined. Data before 2010 when the lower number of examined regional nodes was common may inevitably affect the lymph ratio and result in unstable evidence. In the present study, the median regional nodes examined were 17.96, which was higher than the 16 in the 7th edition AJCC staging system, thus providing a relatively higher level of evidence. Another distinct characteristic of our study is that we only enrolled patients with gastric adenocarcinoma according to histologic subtype codes of the SEER database. The significance of lymph node metastasis is different in different histologic types [30, 31]. Gastric adenocarcinoma comprises nearly 90% of the total number of gastric malignancies and thus focusing on adenocarcinoma helps to better understand the characteristics of this histologic subtype and improve diagnosis and treatment [32].

Although the present study is a relatively large population-based study, it inevitably had several limitations. First, the SEER database is a public open-access cancer registry data and does not include certain information regarding neoadjuvant chemotherapy and surgical complications which may influence the survival of GC patients. Second, the retrospective nature of the SEER database does not allow to extrapolate the results. Third, only 4281 patients were analyzed from a total of 17,988 gastric adenocarcinomas, due to incomplete data. Therefore, the conclusion of this paper is limited to gastric adenocarcinoma. Fourth, in this study, we used data from SEER database only, and lacked independent datasets from our center or other centers. Fifth, because the SEER database lacks information such as the extent of lymph node dissection (D0-2) and the curability (R0-2) of participants, these two factors were not fully considered in this study. Finally, the 8th edition of the AJCC TNM system has been recommended in clinical practice since 2017, but data from the SEER database from after 2017 cannot be used because of the limitation of lack of follow-up information.

In conclusion, by analyzing the SEER database from 2010, when the 7th edition of the AJCC TNM system came into efforts, the present study demonstrates that LND is an indicator of CSS and OS in GC. We calculated two optimal cutoff values of LND as 0.1 and 0.4. Significant differences in survival were observed among LND subgroups in predicting CSS and OS. Patients in each positive N category were found to contain subgroups divided by LND with significantly heterogeneous CSS and OS. Development of a new LND staging strategy may help improve patient care and to better informed and precise treatment decisions. However, due to the retrospective nature of data from the SEER database, further prospective cohort studies are needed.

Conclusion
Through analysis of a population-based SEER database, we found that LND is an independent prognostic factor for GC without distal metastasis. In the current lymph node staging system, LND has potential value in further accurately classifying the GC patients without distal metastasis.

Abbreviations
SEER: Surveillance, Epidemiology, and End Results; GC: Gastric cancer; LND: Lymph node density; CSS: Cancer-specific survival; OS: Overall survival; AJCC: the American Joint Committee on Cancer; TNM: Tumor-node-metastasis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12957-022-02795-9.

Acknowledgements
We would like to thank the staff members of the National Cancer Institute and their colleagues across the United States and at Information management Services, Inc., who have been involved with the SEER Program.

Reporting checklist
The authors have completed the STROBE reporting checklist.

Authors’ contributions
LWQ designed and constructed study. LYH conceived of the study and participated in its design and coordination, collected and assembled the data. LYH, CH, and XXX wrote the manuscript and analyzed the data. All authors read and approved the final manuscript.

Funding
This study received no funding.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660.

2. Chae S, Lee A, Lee JH. The effectiveness of the new (7th) UICC N classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 5th/6th and 7th UICC N classification. Gastric Cancer. 2011. https://doi.org/10.1007/s10434-011-0024-6.

3. Nakagawa M, Choi YY, An JY, Hong JH, Kim JW, Kim HI, et al. Staging for remnant gastric cancer: the metastatic lymph node ratio vs. the UICC 7th Edition System. Ann Surg Oncol. 2016. https://doi.org/10.1245/s10434-016-5390-1.

4. Sacerdotiano VM, Ungureanu BS, Iordache S, Filip MM, Pirici D, Lilic IAM, et al. Accuracy of endoscopic ultrasonography for gastric cancer staging. Curr Health Sci J. 2022. https://doi.org/10.12865/CHSJ.48.01.13.

5. Kim JY, Kim CH, Lee Y, Lee JH, Chae YS. Tumour infiltrating lymphocytes as predictors of lymph node metastasis in early gastric cancers. Pathology. 2017. https://doi.org/10.1016/j.pathol.2017.06.003.

6. Jiao XG, Deng JY, Zhang RP, Wu LL, Wang L, Liu HG, et al. Prognostic value of the number of examined lymph nodes in patients with node-negative gastric cancer. World J Gastroenterol. 2014. https://doi.org/10.3748/wjg.v20.i13.3640.

7. Yang ZL, Zhu MH, Shi Q, Lu FM, Wang CX. Prognostic value of the number of lymph nodes examined in patients with node-negative gastric cancer. J Gastrointest Surg. 2019. https://doi.org/10.1007/s11605-018-3947-y.

8. Go Y, Tanaka H, Tokumoto M, Sakurai K, Toyokawa T, Kubo N, et al. Tumor-associated macrophages extend along lymphatic flow in the pre-metastatic lymph nodes of human gastric cancer. Ann Surg Oncol. 2016. https://doi.org/10.1245/s10434-015-4458-7.

9. Macalindong SS, Kim KH, Ham BH, Ryu KW, Kubo N, Kim JY, et al. Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. BMC Cancer. 2018. https://doi.org/10.1186/s12885-017-3872-6.

10. Deng J, Yamashita H, Seto Y, Liang H. Increasing the number of examined lymph nodes is a prerequisite for improvement in the accurate evaluation of overall survival of node-negative gastric cancer patients. Ann Surg Oncol. 2017. https://doi.org/10.1245/s10434-016-5513-8.

11. Rovio F, Rossi S, Marrelli D, Pedrazzani C, Corso G, Vindigni C, et al. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol. 2006. https://doi.org/10.1002/jso.20566.

12. Chang WC, Lin CS, Yang CY, Lin CK, Chen YW. Lymph node density as a prognostic predictor in patients with betel nut-related oral squa-

13. Cheng WC, Lin CS, Yang CY, Lin CK, Chen YW. Lymph node density as a prognostic predictor in patients with betel nut-related oral squamous cell carcinoma. Clin Oral Investig. 2018. https://doi.org/10.1007/s10278-017-2247-3.

14. Ye LL, Rao J, Fan XW, Ji QH, Hu CS, Ying HM. Impact of tumor dimensions and lymph node density on the survival of patients with hypopharyngeal squamous cell carcinoma. Cancer Manag Res. 2018. https://doi.org/10.2147/cmar.517870.

15. Armit M, Tam S, Boonsrisrijatanon M, Cabanillas ME, Busaidy NL, Grubb EG, et al. Association of lymph node density with survival of patients with papillary thyroid cancer. JAMA Otolaryngol Head Neck Surg. 2018. https://doi.org/10.1001/jamaoto.2017.2416.

16. Cayonu M, Tuna EU, Acar A, Dinc ASK, Sahin MM, Boyneuguer S, et al. Lymph node yield and lymph node density for elective level II-IV neck dissections in laryngeal squamous cell carcinoma patients. Eur Arch Otorhinolaryngol. 2019. https://doi.org/10.1007/s00405-019-05560-z.

17. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010. https://doi.org/10.1245/s10434-010-1362-z.

18. Yang ZL, Zhu MH, Han XJ, Liu QW, Long JH, Wang CX. Modified American Joint Committee on cancer tumor-node-metastasis staging system based on the node ratio can further improve the capacity of prognosis assessment for gastric cancer patients. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00329.

19. Camp RL, Dilled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004. https://doi.org/10.1158/1078-0432.CCR-04-0713.

20. Kerman WN, Viscoli CM, Brass LM, Broderick JP, Trott T, Feldmann E, et al. Phenytoin/propafenone and the risk of hemorhagic stroke. N Engl J Med. 2000. https://doi.org/10.1056/NEJM200012213432501.

21. Meng X, Wang L, Liu G, Zhang J, Wang Y, Yang D, et al. D2 lymphadenectomy with complete mesogastrium excision vs. conventional D2 gastrectomy for advanced gastric cancer. Chin Med J. 2022. https://doi.org/10.1097/CM9.0000000000002023.

22. Kutlu OC, Watchell M, Dissanaike S. Metastatic lymph node ratio success-

23. Li ZY, Zhang QW, Teng LM, Zhang CH, Huang Y. Comparable rates of lymph node metastasis and survival between diffuse type and intestinal type early gastric cancer patients: a large population-based study. Gastrointest Endosc. 2019. https://doi.org/10.1016/j.gie.2019.03.002.

24. Wang X, Appleby DH, Zhang X, Gan L, Wang J, Wan F. Comparison of three lymph node staging schemes for predicting outcome in patients with gastric cancer. Br J Surg. 2013. https://doi.org/10.1002/bjs.9014.

25. Wang ZX, Qiu MZ, Jiang YM, Zhou ZW, Li GX, Xu RH. Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer. J Cancer. 2017. https://doi.org/10.7150/jca.17370.

26. Lee YC, Yang PJ, Zhong Y, Clancy TE, Lin MT, Wang J. Lymph node ratio-based staging system outperforms the Seventh AJCC System for gastric cancer: validation analysis with National Taiwan University Hospital Cancer Registry. Am J Clin Oncol. 2017. https://doi.org/10.1097/COC.0000000000001110.

27. Liu J, Su M, Wang J, Zhang G, Zhou J, Zhang A, et al. A novel grade-lymph node ratio model predicts the prognosis of the advanced gastric cancer patients after neoadjuvant radiotherapy. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.12573.

28. Chen S, Ruo H, Liu J, Geng Q, Guo J, Kong P, et al. Lymph nodes ratio based nomogram predicts survival of resectable gastric cancer regardless of the number of examined lymph nodes. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.17276.

29. Zhou HY, Yang LP, Wang ZX, He NM, Han JP, Zhang DS, et al. Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy. J Cancer. 2018. https://doi.org/10.7150/jca.22016.

30. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehri A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012. https://doi.org/10.3978/j.issn.2078-6891.2012.02.01.

31. Meng NL, Wang YK, Wang HL, Zhou JL, Wang SN. Research on the histological features and pathological types of gastric adenocarcinoma with mucinous differentiation. Front Med (Lausanne). 2022. https://doi.org/10.3389/fmed.2022.29702.

32. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005. https://doi.org/10.1097/01.sla.0000149300.28588.23.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.